318 related articles for article (PubMed ID: 23706570)
1. Tumor associated macrophages in relapsed and refractory Hodgkin lymphoma.
Casulo C; Arcila M; Bohn OL; Teruya-Feldstein J; Maragulia J; Moskowitz CH
Leuk Res; 2013 Sep; 37(9):1178-83. PubMed ID: 23706570
[TBL] [Abstract][Full Text] [Related]
2. Outcome analysis of high-dose chemotherapy and autologous stem cell transplantation in adolescent and young adults with relapsed or refractory Hodgkin lymphoma.
Akhtar S; Rauf SM; Elhassan TA; Maghfoor I
Ann Hematol; 2016 Sep; 95(9):1521-35. PubMed ID: 27376363
[TBL] [Abstract][Full Text] [Related]
3. Mini-BEAM is effective as a bridge to transplantation in patients with refractory or relapsed Hodgkin lymphoma who have failed to respond to previous lines of salvage chemotherapy but not in patients with salvage-refractory DLBCL.
Moore S; Kayani I; Peggs K; Qian W; Lowry L; Thomson K; Linch DC; Ardeshna K
Br J Haematol; 2012 Jun; 157(5):543-52. PubMed ID: 22429186
[TBL] [Abstract][Full Text] [Related]
4. Ifosfamide, idarubicin, and etoposide in relapsed/refractory Hodgkin disease or non-Hodgkin lymphoma: a salvage regimen with high response rates before autologous stem cell transplantation.
Oyan B; Koc Y; Ozdemir E; Kars A; Turker A; Tekuzman G; Kansu E
Biol Blood Marrow Transplant; 2005 Sep; 11(9):688-97. PubMed ID: 16125639
[TBL] [Abstract][Full Text] [Related]
5. F-18 FDG-PET predicts outcomes for patients receiving total lymphoid irradiation and autologous blood stem-cell transplantation for relapsed and refractory Hodgkin lymphoma.
Gentzler RD; Evens AM; Rademaker AW; Weitner BB; Mittal BB; Dillehay GL; Petrich AM; Altman JK; Frankfurt O; Variakojis D; Singhal S; Mehta J; Williams S; Kaminer L; Gordon LI; Winter JN
Br J Haematol; 2014 Jun; 165(6):793-800. PubMed ID: 24628515
[TBL] [Abstract][Full Text] [Related]
6. Prognostic significance of Bcl-2, tumor-associated macrophages, and total neoplastic and inflammatory lymph node involvement in advanced stage classical Hodgkin's lymphoma.
Jakovic LR; Mihaljevic BS; Jovanovic MD; Bogdanovic AD; Andjelic BM; Bumbasirevic VZ
Onkologie; 2012; 35(12):733-9. PubMed ID: 23207618
[TBL] [Abstract][Full Text] [Related]
7. [Efficacy of rituximab-containing salvage regimens on relapsed or refractory B-cell non-Hodgkin's lymphoma].
Huang HQ; Bu Q; Xia ZJ; Lin XB; Wang FH; Li YH; Peng YL; Pan ZH; Wang SS; Lin TY; Jiang WQ; Guan ZZ
Ai Zheng; 2006 Apr; 25(4):486-9. PubMed ID: 16613686
[TBL] [Abstract][Full Text] [Related]
8. Ifosfamide, etoposide, cytarabine, and dexamethasone as salvage treatment followed by high-dose cyclophosphamide, melphalan, and etoposide with autologous peripheral blood stem cell transplantation for relapsed or refractory lymphomas.
Schütt P; Passon J; Ebeling P; Welt A; Müller S; Metz K; Moritz T; Seeber S; Nowrousian MR
Eur J Haematol; 2007 Feb; 78(2):93-101. PubMed ID: 17313557
[TBL] [Abstract][Full Text] [Related]
9. Does the addition of involved field radiotherapy to high-dose chemotherapy and stem cell transplantation improve outcomes for patients with relapsed/refractory Hodgkin lymphoma?
Kahn S; Flowers C; Xu Z; Esiashvili N
Int J Radiat Oncol Biol Phys; 2011 Sep; 81(1):175-80. PubMed ID: 20732769
[TBL] [Abstract][Full Text] [Related]
10. Long-term results of autologous stem cell transplantation for primary refractory or relapsed Hodgkin's lymphoma.
Majhail NS; Weisdorf DJ; Defor TE; Miller JS; McGlave PB; Slungaard A; Arora M; Ramsay NK; Orchard PJ; MacMillan ML; Burns LJ
Biol Blood Marrow Transplant; 2006 Oct; 12(10):1065-72. PubMed ID: 17084370
[TBL] [Abstract][Full Text] [Related]
11. Prognostic factors and long-term outcome of autologous haematopoietic stem cell transplantation following a uniform-modified BEAM-conditioning regimen for patients with refractory or relapsed Hodgkin lymphoma: a single-center experience.
Czyz A; Lojko-Dankowska A; Dytfeld D; Nowicki A; Gil L; Matuszak M; Kozlowska-Skrzypczak M; Kazmierczak M; Bembnista E; Komarnicki M
Med Oncol; 2013; 30(3):611. PubMed ID: 23702734
[TBL] [Abstract][Full Text] [Related]
12. Intensive conditioning regimen of etoposide (VP-16), cyclophosphamide and carmustine (VCB) followed by autologous hematopoietic stem cell transplantation for relapsed and refractory Hodgkin's lymphoma.
Benekli M; Smiley SL; Younis T; Czuczman MS; Hernandez-Ilizaliturri F; Bambach B; Battiwalla M; Padmanabhan S; McCarthy PL; Hahn T
Bone Marrow Transplant; 2008 Apr; 41(7):613-9. PubMed ID: 18071290
[TBL] [Abstract][Full Text] [Related]
13. Risk factors predicting outcomes for primary refractory hodgkin lymphoma patients treated with salvage chemotherapy and autologous stem cell transplantation.
Shah GL; Yahalom J; Matasar MJ; Verwys SL; Goldman DA; Bantilan KS; Zhang Z; McCall SJ; Moskowitz AJ; Moskowitz CH
Br J Haematol; 2016 Nov; 175(3):440-447. PubMed ID: 27377168
[TBL] [Abstract][Full Text] [Related]
14. High-dose sequential chemotherapy and peripheral blood progenitor cell autografting in patients with refractory and/or recurrent Hodgkin lymphoma: a multicenter study of the intergruppo Italiano Linfomi showing prolonged disease free survival in patients treated at first recurrence.
Tarella C; Cuttica A; Vitolo U; Liberati M; Di Nicola M; Cortelazzo S; Rosato R; Rosanelli C; Di Renzo N; Musso M; Pavone E; Santini G; Pescarollo A; De Crescenzo A; Federico M; Gallamini A; Pregno P; Romano R; Coser P; Gallo E; Boccadoro M; Barbui T; Pileri A; Gianni AM; Levis A
Cancer; 2003 Jun; 97(11):2748-59. PubMed ID: 12767087
[TBL] [Abstract][Full Text] [Related]
15. Autologous stem cell transplant for early relapsed/refractory Hodgkin lymphoma: results from two transplant centres.
Smith SD; Moskowitz CH; Dean R; Pohlman B; Sobecks R; Copelan E; Andresen S; Bolwell B; Maragulia JC; Vanak JM; Sweetenham J; Moskowitz AJ
Br J Haematol; 2011 May; 153(3):358-63. PubMed ID: 21410449
[TBL] [Abstract][Full Text] [Related]
16. Results of a Multicenter Phase II Trial of Brentuximab Vedotin as Second-Line Therapy before Autologous Transplantation in Relapsed/Refractory Hodgkin Lymphoma.
Chen R; Palmer JM; Martin P; Tsai N; Kim Y; Chen BT; Popplewell L; Siddiqi T; Thomas SH; Mott M; Sahebi F; Armenian S; Leonard J; Nademanee A; Forman SJ
Biol Blood Marrow Transplant; 2015 Dec; 21(12):2136-2140. PubMed ID: 26211987
[TBL] [Abstract][Full Text] [Related]
17. Prognostic value of lymphocyte/monocyte ratio in advanced Hodgkin lymphoma: correlation with International Prognostic Score and tumor associated macrophages.
Jakovic LR; Mihaljevic BS; Andjelic BM; Bogdanovic AD; Perunicic Jovanovic MD; Babic DD; Bumbasirevic VZ
Leuk Lymphoma; 2016 Aug; 57(8):1839-47. PubMed ID: 26727349
[TBL] [Abstract][Full Text] [Related]
18. Ifosfamide and vinorelbine is an effective reinduction regimen in children with refractory/relapsed Hodgkin lymphoma, AHOD00P1: a children's oncology group report.
Trippett TM; Schwartz CL; Guillerman RP; Gamis AS; Gardner S; Hogan S; London WB; Chen L; de Alarcon P
Pediatr Blood Cancer; 2015 Jan; 62(1):60-4. PubMed ID: 25308760
[TBL] [Abstract][Full Text] [Related]
19. The prognostic impact of tumour-associated macrophages and Reed-Sternberg cells in paediatric Hodgkin lymphoma.
Gupta S; Yeh S; Chami R; Punnett A; Chung C
Eur J Cancer; 2013 Oct; 49(15):3255-61. PubMed ID: 23791542
[TBL] [Abstract][Full Text] [Related]
20. [High-dose chemotherapy and autologous stem cell transplantation for refractory and relapsing Hodgkin's disease as first-line therapy-- studies at Sheba Medical Center--Tel Hashomer].
Avigdor A; Hardan I; Shpilberg O; Raanani P; Grotto I; Ben-Bassat I
Harefuah; 2000 Sep; 139(5-6):174-9, 248, 247. PubMed ID: 11062945
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
